fda update on tirzepatide BREAKING NEWS!!! A weight loss drug more effective than Semaglutide has been approved by the today. (Zepbound for weight loss and Mounjaro for diabetes) showed a 15-20.9% weight change in FDA to reconsider removal of

GLP2 Mechanism of Action GLP2 exerts its therapeutic effects through a unique dual agonist mechanism, simultaneously activating both GIP and GLP-1 receptors with distinct pharmacological properties at each target

To better understand this progress, we'll explore how GLP-1 medications address obesity and its related health challenges

It is worth noting that the use of semaglutide for patients without diabetes increased by over 256% between 2018 and 2022

There is a FDA-approved semaglutide weight loss medication called Wegovy

In this regard, semaglutide is becoming increasingly important, as demonstrated in Table 3, which summarizes the previous results of phase 3 clinical trials